Nykredit A S Makes New $20.64 Million Investment in Edwards Lifesciences Corporation $EW

Nykredit A S acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 228,193 shares of the medical research company’s stock, valued at approximately $20,642,000.

Other institutional investors also recently modified their holdings of the company. Robbins Farley increased its stake in Edwards Lifesciences by 4.1% in the second quarter. Robbins Farley now owns 25,269 shares of the medical research company’s stock valued at $2,286,000 after purchasing an additional 1,005 shares in the last quarter. Natural Investments LLC boosted its position in shares of Edwards Lifesciences by 17.3% during the 2nd quarter. Natural Investments LLC now owns 6,450 shares of the medical research company’s stock worth $583,000 after purchasing an additional 950 shares in the last quarter. Midwest Professional Planners LTD. grew its stake in shares of Edwards Lifesciences by 5.2% in the 2nd quarter. Midwest Professional Planners LTD. now owns 31,125 shares of the medical research company’s stock valued at $2,816,000 after buying an additional 1,546 shares during the period. Investors Research Corp grew its stake in shares of Edwards Lifesciences by 855.3% in the 2nd quarter. Investors Research Corp now owns 898 shares of the medical research company’s stock valued at $81,000 after buying an additional 804 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $262,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $89.89 on Friday. The company has a fifty day moving average price of $89.74 and a 200-day moving average price of $85.46. The firm has a market cap of $51.76 billion, a price-to-earnings ratio of 51.66, a PEG ratio of 2.38 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the firm earned $0.67 earnings per share. The firm’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. BTIG Research boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Mizuho increased their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Transactions at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president directly owned 14,868 shares of the company’s stock, valued at $1,353,880.08. The trade was a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,045 shares of company stock worth $457,749 in the last 90 days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.